Wading into parallel reviews as a reimbursement strategy

The process of gaining reimbursement is one of the most expensive and perilous activities a medical technology company will undergo. Some are exploring how (and whether) a strategy that encourages working with both FDA and CMS at the same time can help cut down the resource costs associated with reimbursement. Seth Goldenberg, director of product